HS218, a new FXR specific antagonist, suppressed liver gluconeogenesis and effectively improved glucose homeostasis in db/db and HFD-induced T2D mice by inhibiting Fxr binding to PGC-1α promoter (Xu et al., 2018). This evidence concerns the gene NR1H4 and type 2 diabetes mellitus.